Appendix B

Committee and Speaker Biosketches

PLANNING COMMITTEE BIOSKETCHES

LESLIE G. BIESECKER (he/him/his), MD, is distinguished investigator and director of the Center for Precision Health Research at the National Human Genome Research Institute of the National Institutes of Health, which he joined in 1993. He uses genetic and genomic technologies to study the etiology of genetic disorders and has published more than 300 primary research articles, reviews, and chapters. Biesecker developed the ClinSeq^® program, which began clinical genomics research in 2006, before the widespread availability of next-generation sequencing. He is double board certified in pediatrics and medical genetics. Biesecker was elected to the National Academy of Medicine in 2016 and was president of the American Society of Human Genetics for 2019.

NATASHA BONHOMME (she/her/hers) is founder of Expecting Health, an organization born from Genetic Alliance and dedicated specifically to sharing science-based and policy-informed information that reflects the lived experiences of individuals and their families. A direct product of her role as chief strategy officer at Genetic Alliance, where she has overseen the organization’s maternal and child health initiatives, Expecting Health accomplishes its mission by bringing a range of consumer and professional stakeholders together to address the need for clear, science-based information for families and individuals through tangible, actionable messages. As director of Baby’s First Test, Bonhomme has testified before the U.S. Senate Health, Education, Labor and Pension Committee’s Subcommittee

on Children and Families on the importance of public education for newborn screening. She serves on a range of committees, including (as co-chair) the Genetics and Bioethics Committee, American Public Health Association; the Association of Public Health Laboratories Committee on Newborn Screening and Genetics in Public Health; and the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children. Bonhomme is co-chair of the Developing Leaders Program for Planned Parenthood of Metropolitan Washington. She obtained a certificate from Georgetown University in nonprofit executive management.

JEFFREY R. BOTKIN (Chair, he/him/his), MD, MPH, is emeritus professor of pediatrics and was adjunct professor of human genetics and internal medicine at the University of Utah. He is the past chief of the Division of Medical Ethics and Humanities and served for 17 years as associate vice president for research integrity. Botkin chaired the Advisory Committee on Human Research Protections with the U.S. Department of Health and Human Services and was a member of the Secretary’s Advisory Committee on Heritable Diseases in Newborns. He serves on the Food and Drug Administration’s Pediatric Ethics Subcommittee and chairs the National Institutes of Health’s (NIH’s) Embryonic Stem Cell Eligibility Working Group. Botkin received consistent NIH funding for research on the ethical, legal, and social implications of genetic technologies with a particular emphasis on research ethics, biobanking, newborn screening, and prenatal diagnosis. He served on the planning committee for the 2014 National Academies of Sciences, Engineering, and Medicine’s workshop on Guidelines for Returning Individual Results for Genome Research Using Population-Based Banked Specimens and chaired the 2018 consensus committee that produced a publication titled Returning Individual Research Results to Participants: Guidance for a New Research Paradigm. Botkin is a graduate of Princeton University and received an MD from the University of Pittsburgh, and an MPH from Johns Hopkins University.

ADAM H. BUCHANAN (he/him/his), MS, MPH, is associate professor and director of the Genomic Medicine Institute at Geisinger. He is interim director of Geisinger’s MyCode Genomic Screening and Counseling program, which screens biobank participants’ exomes for clinically actionable findings associated with increased risk for cancer, cardiovascular disease, and other conditions. Buchanan is a National Institutes of Health-funded investigator and board-certified and licensed genetic counselor with expertise in assessing genetic counseling outcomes and cancer risk management behaviors. He is also a former president of the American Board of Genetic Counseling. Buchanan’s research interests include outcomes of genomic screening, delivery of genetics services, and performance of multicancer

early detection tests. He has completed training in implementation science from the National Cancer Institute. Buchanan received a master’s in public health with focus in health behavior science from the University of North Carolina at Chapel Hill, and a master’s in science in genetic counseling from the University of North Carolina at Greensboro.

DANA C. CRAWFORD (she/her/hers), PhD, is professor of population and quantitative health sciences at Case Western Reserve University (CWRU) and associate director for population and diversity research in the CWRU Cleveland Institute for Computational Biology. She also holds a secondary appointment in CWRU’s Department of Genetics and Genome Sciences. Crawford’s expertise is in genetic epidemiology and human genetics, and her current research interests map to the interface of genetic epidemiology and big data biomedical informatics. Her laboratory accesses epidemiologic and clinical collections to characterize common and rare genetic variants associated with human diseases in diverse populations. Crawford also has an interest in identifying pleiotropy and environmental modifiers of these genetic associations, including pharmacogenomics. She is a three-time Kavli Frontiers in Science Fellow, and she was elected as fellow of the American Association for the Advancement of Science in biological sciences for “distinguished contributions in pioneering phenome-wide association studies and in developing and leading genetic studies in under-represented minority populations.” Crawford earned her BS from Vanderbilt University and a PhD from Emory University in the Genetics and Molecular Biology Program.

DAVID FORSTER (he/him/his), JD, joined Western Institutional Review Board in 1996 and is currently chief compliance officer and chief privacy officer for WCG IRB (formerly known as Western Institutional Review Board-Copernicus Group). He co-chairs the Secretary’s Advisory Committee on Human Research Protections (SACHRP) Sub-Committee on Harmonization. Forster previously served a four-year term as a member of SACHRP and was a member of the SACHRP Sub-Committee on Inclusion of Individuals with Impaired Decision-Making in Research. He also served on the Certified Institutional Review Board Professional Council. In his role on the SACHRP subcommittee, Forster worked on drafting SACHRP’s five recommendations regarding the return of research results to research subjects. Forster also provided input on the All of Us study consent form during its development. He has expertise in bioethics, laws and regulations governing the protection of human subjects in research, and privacy. Forster has a JD and a master’s in medical ethics from the University of Washington.

INGRID A. HOLM (she/her/hers), MD, MPH, is professor of pediatrics at Harvard Medical School (HMS), faculty in the Division of Genetics and

Genomics and the Division of Endocrinology at Boston Children’s Hospital (BCH), and faculty at the HMS Center for Bioethics. She is associate director of Robert’s Program for Sudden Unexpected Death in Pediatrics (SUDP), where she leads studies to identify genetic contributions to SUDP; she is also a member of the Harvard Undiagnosed Disease Network site. Additionally, Holm is co-principal investigator, with Robert Green, of the BabySeq2 project of a National Center for Advancing Translational Sciences–funded U01. She was co-investigator of the BCH/Brigham and Women’s Hospital U19 “BabySeq” project. She has been a member of the National Human Genome Research Institute-funded Electronic Medical Records and Genomics Network for over a decade. Holm conducts empirical, mixed-methods research to study the impact of returning genomic information. She is a pediatric geneticist with clinical focus on bone diseases, disorders of sex development, and rare disease research. Holm completed her pediatric residency and dual fellowship in medical genetics and pediatric endocrinology at BCH, and earned the Harvard Pediatric Health Services Research Fellowship and an MPH at the Harvard School of Public Health.

SPEAKER BIOSKETCHES

NOURA ABUL-HUSN (she/her/hers), PhD, MD, is vice president of Genomic Health at 23andMe and associate professor of medicine at the Icahn School of Medicine at Mount Sinai. She is principal investigator in the Electronic Medical Records and Genomics Network, which is integrating polygenic risk scores into clinical care. Abul-Husn recently joined 23andMe as vice president of genomic health to develop strategies for genome-informed disease prevention and management. Her scientific contributions include pioneering genome-first approaches in electronic health record-linked biobanks to provide novel clinical insights and inform therapeutic discovery. In her role at Mount Sinai, Abul-Husn launched a genomic-screening program tailored to ancestrally diverse biobank participants. She previously served as director of translational genetics at the Regeneron Genetics Center, during which time she received a 40 under 40 Rising Star Award. Abul-Husn received the Dr. Michael S. Watson Genetic & Genomic Medicine Innovation Award from the American College of Medical Genetics and Genomics’ Foundation for Genetic and Genomic Medicine. She completed her MD, PhD, and residency at Mount Sinai in New York, and was elected to the Alpha Omega Alpha Medical Honor Society. Abul-Husn is board certified in internal medicine and medical genetics.

DAVID BICK (he/him/his), MD, is principal clinician for the Newborn Genomes Programme at Genomics England. Prior to his work in England, he was chief medical officer and a faculty investigator at the HudsonAlpha

Institute for Biotechnology. Bick also served as medical director of the Smith Family Clinic for Genomic Medicine, located on the campus of HudsonAlpha Institute for Biotechnology, and he was laboratory director of the HudsonAlpha Clinical Services Laboratory. He came to HudsonAlpha from the Medical College of Wisconsin, where he was professor in the Department of Pediatrics and the Department of Obstetrics & Gynecology. Bick’s laboratories were the first in the world to offer whole-genome sequencing as a clinical test, and he developed the first genomic medicine clinic in the United States. He received his medical degree from George Washington University School of Medicine in 1981 and completed his residency in pediatrics at Yale-New Haven Hospital in New Haven, Connecticut. There Bick completed a fellowship in human genetics and pediatrics in 1986, followed by a postdoctoral research fellowship in human genetics in 1987. He is board certified in pediatrics, clinical genetics, and clinical molecular genetics.

KATHERINE BLIZINSKY (she/her/hers), PhD, is policy director for the All of Us Research Program, leading program policy activities, including legislative and regulatory policy analysis, as well as the development and strategic visioning for work regarding ethical, legal, and social implications (ELSI). On Capitol Hill, she worked with the Senate Health, Education, Labor, and Pensions Committee under Ranking Member Patty Murray, where, among other roles, she helped lead the drafting and negotiation of the 21st Century Cures Act. Blizinsky has policy experience with both the legislative and executive branches. She has drawn on her expertise in the areas of data governance, genomics, and ethical research conduct to her work at All of Us. A neuroscientist and geneticist specializing in gene–environment interaction, Blizinsky continues to be involved in academic research and lectures frequently on genomics, neuroscience, legal and regulatory policy, and ELSI.

YVONNE BOMBARD (she/her), PhD, is a genomics health services researcher and scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto. She is associate professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto and directs the Genomics Health Services Research Program at St. Michael’s Hospital. Bombard holds the Canada research chair in genomics health services and policy. She sets research direction at national and international levels as a board member of the American Society of Human Genetics and the Canadian Institutes of Health Research’s (CIHR’s) Institute of Genetics. Bombard advises on funding recommendations for emerging genetic testing technologies for Ontario. She was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence

and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health and received a Rising Star award from CIHR’s Institute of Health Services and Policy Research. Bombard has been awarded a CIHR Foundation grant as an early career investigator, the CIHR Maud Menten Early Career Prize in Genetics, and the Canadian Cancer Society’s early career investigator award for her work and policy change.

BETH COLLINS (she/they), MA, is a contractor for Columbus Technologies and Services. She currently works with the National Institutes of Health’s All of Us Research Program to ensure Investigational Device Exemption (IDE) sponsor communications and essential documentation meet compliance under 21 C.F.R. 812. In their career as a certified clinical research professional and bioethicist, Collins has worked with more than 30 investigator-initiated early-phase studies requiring either an investigational new drug application or IDE from the Food and Drug Administration, ranging from novel drug combinations (hematological malignancies) to implantable medical devices. She is also an interdisciplinary artist and graduate student in Virginia Commonwealth University’s MATX doctoral program, performing research at the intersection of arts and medical innovation.

STEPHANIE DEVANEY (she/her/hers), PhD, is chief operating officer of the All of Us Research Program at the National Institutes of Health (NIH). In this role, she is responsible for overseeing operations, ensuring the program fulfills its mission of advancing precision medicine research. Prior to this, Devaney led the coordination of the Precision Medicine Initiative from the Office of the Chief of Staff at the White House. In this role, she coordinated the many components of the initiative and guided the vision of the overall effort, along with the many federal partners. Before joining the White House, Devaney worked in the Office of the Director at NIH, where she helped advance policies critical to biomedical research and the NIH mission, and assisted in the development of programs and research initiatives to advance national scientific priorities. She received her PhD in molecular genetics from The George Washington University and her BS in biology from The Ohio State University.

GAI ELHANAN, MD, is a veteran physician (internal medicine and infectious diseases), health care researcher, and data scientist. He is currently a clinical data research scientist with the Center for Genomic Medicine at the Desert Research Institute and the Healthy Nevada Project in Reno, Nevada. Elhanan has more than 25 years of experience with health care information systems, including research, design, development, and implementation in clinical and administrative environments. He possesses unique knowledge in the field of semantic networks and medical and health care

ontologies. Elhanan’s formal medical informatics education involved completing a postdoctoral fellowship at the medical informatics department of the Presbyterian Medical Center at Columbia University.

JOSEPH GRZYMSKI (he/him/his), PhD, is chief scientific officer of Renown Health, director of the Renown Institute for Health Innovation, and faculty member at the Desert Research Institute. He conceived of and leads the Healthy Nevada Project, a population genetics study that has enrolled, consented, and collected DNA and other health determinants data from more than 50,000 participants throughout Nevada. Grzymski is principal investigator (PI) of a genetics study on risk for nonalcoholic steatohepatitis, which is sponsored by Gilead Sciences; he is also PI of a National Institutes of Health R01 grant, focusing on gene and environment interactions. Through the Nevada Public Health Foundation and an array of high-impact papers, he and his team have helped transform northern Nevada into a hotspot of population health. Grzymski works closely with a variety of federal agencies on population genomics best practices. He received his PhD from Rutgers University, and was a postdoctoral fellow at Rockefeller University, a Fulbright scholar, and a Bowdoin College graduate.

BRUCE KORF (he/him/his), MD, PhD, is associate dean for genomic medicine and chief genomics officer at University of Alabama at Birmingham (UAB), and Wayne H. and Sara Crews Finley endowed chair in medical genetics at the UAB Heersink School of Medicine. He is a medical geneticist who is certified by the American Board of Medical Genetics and Genomics in clinical genetics, clinical cytogenetics, and clinical molecular genetics. Korf is also certified by the American Board of Pediatrics and the American Board of Psychiatry and Neurology (child neurology). He is coeditor of Emery and Rimoin’s Principles and Practice of Medical Genetics and editor-in-chief of the American Journal of Human Genetics. Korf’s major research interests are the diagnosis and treatment of neurofibromatosis and the integration of genomics into medical practice.

MATTHEW LEBO (he/him/his), PhD, is chief laboratory director of the Laboratory for Molecular Medicine, a molecular diagnostics laboratory certified by the Clinical Laboratory Improvement Amendments, and director of bioinformatics within Mass General Brigham Personalized Medicine. He is associate professor of pathology at Harvard Medical School and an associate member of the Broad Institute of MIT and Harvard. Lebo’s research focuses on driving forward the routine use of genomics and computational biology in translational and clinical applications, specifically in genomic-based applications and high-throughput screening of unaffected individuals. He also participates in standards and guidelines development,

including co-chairing the ClinGen Low-Penetrance/Risk Allele Work Group and being involved in activities with the American College of Medical Genetics and Genomics, Association for Molecular Pathology, College of American Pathologists, the National Society of Genetic Counselors, the Clinical and Laboratory Standards Institute, and the Medical Genome Initiative.

KATHLEEN A. LEPPIG (she/her/hers), MD, is chief of genetic services at Kaiser Permanente of Washington and clinical professor in the Department of Medical Genetics at the University of Washington. She is a medical geneticist who is certified by the American Board of Medical Genetics and Genomics in clinical genetics and clinical cytogenetics. Leppig is involved in the development of genetic and genomic services for Kaiser Permanente, focusing on how best to provide these services across a large population. She has a 16-year collaboration with Vietnam National Hospital of Pediatrics to support the development of medical genetics care in Vietnam. Leppig is a section editor for Genetics in Medicine. She is involved in a number of research projects including a health care system-led familial risk notification project and the Cascade Traceback study for women with a history of ovarian cancer. Leppig is a clinical lead at the Pacific Northwest Site for the Undiagnosed Disease Network.

DAVID MAGNUS, PhD, is Thomas A. Raffin professor of medicine and biomedical ethics, and professor of pediatrics, medicine, and (by courtesy) bioengineering, and associate dean of research at Stanford University. He is director of the Stanford Center for Biomedical Ethics, a member of the Stanford Hospital and Clinics Ethics Committee, past president of the Association of Bioethics Program Directors, and editor-in-chief of the American Journal of Bioethics. Magnus is currently vice-chair of the Institutional Review Board (IRB) for the National Institutes of Health Precision Medicine Initiative (All of Us). He is a member of Stanford’s IRB and Stem Cell Research Oversight Committee, and has extensive experience as a research ethics consultant. Magnus’s research focuses on a wide range of topics in bioethics, including research ethics, the ethics of comparative effectiveness research, transplant ethics, genetics/genomics, and issues in patient/physician communication and artificial intelligence and machine learning in medicine.

AMY MCGUIRE (she/her/hers), JD, PhD, is Leon Jaworski professor of biomedical ethics and director of the Center for Medical Ethics and Health Policy at Baylor College of Medicine. Currently, she is on the board of the Greenwall Foundation, is a Hasting’s Center Fellow, and is a member of the Scientific Advisory Board for Geisinger Research and The Morgridge

Institute for Research. McGuire has served as a member of the National Advisory Council for Human Genome Research and as an advisor to the X Prize in Genomics. She researches ethical and policy issues related to emerging technologies and innovative therapeutics, with a particular focus on genetics and genomics, big data, neuropsychology, and the clinical integration of novel neurological devices. Her research is funded by the National Institutes of Health. McGuire has received numerous teaching awards at Baylor College of Medicine, was recognized by Texas Executive Women as a Woman on the Move, and was invited to give two TED talks.

MICHELLE N. MEYER (she/her/hers), JD, PhD, is associate professor and chair of the Department of Bioethics and Decision Sciences at Geisinger, where she is also faculty codirector of the Behavioral Insights Team in Geisinger’s Steele Institute for Health Innovation. In addition to engaging in normative and legal scholarship, Meyer empirically investigates judgments and decision-making in the areas of health care, science, and innovation using experimental and other methods. For instance, she is completing a National Institutes of Health-funded randomized clinical trial comparing standard, in-person consent with Geisinger’s MyCode biobank, which includes the return of clinically actionable results to an eConsent codeveloped with those who designed the eConsent used by All of Us. Meyer earned a PhD in religious studies, with a focus on applied ethics, from the University of Virginia and a JD from Harvard Law School, where she was an editor of the Harvard Law Review. Following law school, she clerked on the U.S. Court of Appeals for the Eleventh Circuit.

BRIAN C. MOYER (he/him/his), PhD, is director of the U.S. National Center for Health Statistics (NCHS), where he provides executive leadership and strategic direction for the center’s statistical programs and policies. He serves as senior advisor to the Centers for Disease Control and Prevention and to the secretary of the U.S. Department of Health and Human Services; he also serves as Statistical Official for the department. Prior to joining NCHS, Moyer spent more than 25 years with the U.S. Department of Commerce. He served as director of the Bureau of Economic Analysis, where he led modernization efforts to improve official economic statistics, including the measures of gross domestic product. Moyer received bachelor’s and master’s degrees in economics from the University of Maryland and a PhD in economics from American University.

DUONG “TONY” NGUYEN (he/him/his), DO, is a pediatrician who has worked as an active-duty Army physician, in private practice, and at the local health department level before returning to federal service as an active-duty public health service officer. He began his career at the

Centers for Disease Control and Prevention as a member of the Epidemic Intelligence Service (EIS) assigned to the National Health and Nutrition Examination Survey (NHANES). After EIS, Nguyen became NHANES’s chief medical officer and served as acting chief of the Operations Branch. He also currently serves as the human subjects contact for NHANES. As chief medical officer, Nguyen provides the clinical oversight for health examinations, provides medical input to NHANES planning and operations, and is the medical point of contact for participants or medical providers regarding NHANES test results. He attended medical school at the Lake Erie College of Osteopathic Medicine and completed residency at Walter Reed Army Medical Center.

JULIE C. SAPP (she/her/hers), ScM, CGC, works as part of a multidisciplinary research team at the Center for Precision Health Research at the National Human Genome Research Institute, where she draws upon her genetic counseling training and more than a decade of behavioral science research experience to promote the integration of genomics into medical practice. The diverse clinical research portfolio of the laboratory and her role as primary clinician working directly with research participants has positioned her to investigate a varied set of important social and behavioral questions related to clinical genomics and genetic counseling. Sapp’s work in this area has included qualitative and quantitative investigations of social and behavioral constructs, such as the psychosocial impact of genetic disease, patient attitudes and beliefs, decision-making, research ethics, and informed consent. More recently, she has extended her early work to include applying these approaches to understand how best to meet the clinical demands of the expanding role of genome and exome sequencing and how to maximize the utility of genomic findings. Sapp’s research focus in these efforts is to investigate the clinical utility of genomic techniques to develop best practices for the return of results and inform future studies of the expanding role of genomics.

ALAN SIMON (he/him/his), MD, is director of the Division of Health and Nutrition Examination Surveys at the National Center for Health Statistics (NCHS). Prior to this, he was a medical officer/project scientist for the Institutional Developmental Awards Program’s States Pediatric Clinical Trials Network in the Environmental influences on Child Health Outcomes program. Simon also worked in the National Institutes of Health Office of the Director, where he focused on clinical trials engaging children in underserved states. Previously, he worked in the U.S. Department of Health and Human Services Office on Women’s Health in the Office of the Assistant Secretary for Health, where his work within women’s and girls’ health included sports participation, eating disorders, and opioid misuse.

Simon also has a decade of experience as a medical officer in the Office of Analysis and Epidemiology and the Division of Health Care Statistics at NCHS. He has authored more than 70 publications in the areas of health, health services, and epidemiology. Simon received a BA in economics from Cornell University and an MD from Columbia University College of Physicians and Surgeons. He completed his residency in pediatrics at Children’s National Medical Center in Washington, DC. After Simon’s residency, he was a Robert Wood Johnson clinical scholar at Johns Hopkins University.

BEN SOLOMON (he/him/his), PhD, is clinical director of the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health; he also leads an NHGRI research group that focuses on the use of artificial intelligence to analyze datasets relevant to genetic conditions. He trained in clinical genetics and pediatrics through a joint NHGRI/Children’s National Medical center program. Prior to rejoining NHGRI as clinical director in 2019, Solomon served as chief of the Division of Medical Genomics at the Inova Translational Medicine Institute, and was managing director of GeneDx, a clinical and research genetics/genomics sequencing lab. He received his medical degree from Dartmouth.

NATASHA STRANDE, PhD, is assistant professor within the department of Genomic Health and Autism and Developmental Medicine Institute at Geisinger, and clinical laboratory director for the MyCode Community Health Initiative. As clinical laboratory director for Geisinger’s Precision Health Program, she oversees the MyCode Biobank and the variant interpretation team that screens exome data generated through the MyCode DiscovEHR collaboration to identify clinically actionable variants for return by the Genomic Screening and Counseling team. Strande received her BS in biochemistry from Denison University and continued her scientific training at University of North Carolina (UNC) at Chapel Hill, where she received her PhD in biochemistry and biophysics, followed by postdoctoral training in the Department of Genetics. She completed her molecular genetics and cytogenetics laboratory fellowships at UNC and is board certified in laboratory genetics and genomics by the American Board of Medical Genetics and Genomics.

AMY STURM (she/her/hers), MS, is director of population health genomics at 23andMe. Previously, she was professor and genetic counselor in the Geisinger Genomic Medicine Institute for five years, where she served as principal investigator of the MyCode Community Health Initiative and director of the MyCode Genomic Screening and Counseling Program. From 2019 to 2022, Sturm served as chair of the Advisory Board to the Genetic Counseling Resource for the National Institutes of Health’s (NIH’s) All of

Us Research Program. During her time at Geisinger, she was also principal investigator of an NIH-funded grant that utilized tools from implementation science to develop patient-centered identification and cascade testing programs for familial hypercholesterolemia. Before Sturm’s time at Geisinger, she was associate professor and genetic counselor in the Division of Human Genetics at the Ohio State University Medical Center. She served as the 2019 president of the National Society of Genetic Counselors, and serves on the American Heart Association’s Genomic and Precision Medicine leadership council, the MVP-Return of Actionable Results Advisory Committee, and the Scientific Advisory Board of the Family Heart Foundation.

JASON VASSY (he/him/his), MD, MPH, is associate professor of medicine at Harvard Medical School, a clinician-investigator at the Veterans Affairs (VA) Boston Healthcare System and Brigham and Women’s Hospital, and a founding member of Precision Population Health at Ariadne Labs. He is a practicing primary care internist and researcher in the implementation and evaluation of genomic medicine interventions. For the last decade, Vassy has directed the Genomes2Veterans Research Program at VA Boston, where his research examines the clinical utility of genetic and genomic testing in various primary care clinical contexts. Current projects include clinical trials of pharmacogenetic testing, polygenic risk scores, and return of unanticipated genetic results among participants of the Million Veteran Program. He is also principal investigator for the VA All of Us Research Program. Vassy earned his MD from Washington University School of Medicine before completing an internal medicine residency at the University of Pennsylvania, as well as a Harvard general internal medicine research fellowship at Massachusetts General Hospital.

MARC S. WILLIAMS (he/him/his), MD, is a clinical geneticist and research scientist. He is professor and director emeritus of Geisinger’s Department of Genomic Health. Williams is on the National Human Genome Research Institute’s Genomic Medicine working group, and was a member of the Secretary’s Advisory Committee for Genetics, Health and Society. He is currently president of the American College of Medical Genetics and Genomics (ACMG). Williams is also past chair of the ACMG Committee on the Economics of Genetic Services and founded the ACMG Quality Improvement Special Interest Group. He is a member of the Scientific Advisory Boards of the Clinical Pharmacogenetic Implementation Consortium, the National Institutes of Health Undiagnosed Diseases Project, and the Online Mendelian Inheritance in Man project. Williams has authored more than 200 articles on a variety of topics, including the economic evaluation and value of genetic services, implementation of genomic medicine, and the use of informatics to facilitate genomic medicine and precision health.

ANASTASIA WISE, PhD, is director of scientific return to participants and impact for the All of Us Research Program and leads the responsible return of genomic results to participants. Prior to joining the All of Us Research Program, she worked at the National Human Genome Research Institute, where she served as program director for the National Institutes of Health Common Fund’s Undiagnosed Diseases Network, building a sustainable national resource to diagnose both rare and previously undiagnosed diseases through team science. Wise also managed the Newborn Sequencing in Genomic Medicine and Public Health program, exploring the potential implications, challenges, and opportunities associated with the possible use of genomic sequence information in the newborn period. Her other research interests include gene–environment interactions in complex disease; pharmaco- and toxicogenomics; and ethical, legal, and social issues related to the use of genetic information. Wise received her PhD in genetics and genomics from Duke University, and her BS in environmental science from the University of North Carolina at Chapel Hill.

This page intentionally left blank.